Fresh from FDA approval for its paediatric stem-cell product, Mesoblast is pursuing consent for indications of heart disease ...

Biotech investing can be tricky. Often, the drugs that these fledgling companies produce don’t pan out, and shareholders take ...

Don’t look now, but Cathie Wood of Ark Invest is fresh off an impressive comeback year, with her broader basket of disruptive ...

Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 ...

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

The companies Immunovant, Verdiva Bio, and Akero Therapeutics bagged the biggest biotech funding rounds overall in January ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Radiopharmaceuticals biotech AdvanCell has pulled together a $112 million Series C about two years after its much smaller ...

The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

Robert F. Kennedy Jr. may soon be America's top pharmaceutical regulator. That is cause for concern in Seattle’s biotech ...

Hundreds of Cambridge and Plainville biotech employees are facing layoffs by March 30, state filings show. Thermo Fisher Scientific, a Waltham-based biotech company, is cutting 300 positions across ...

After a nearly $300 million IPO little more than a year ago, a young Peninsula biotech company will discontinue what had been ...